Author

R. C. Rintoul

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. Peryt· 1 shared A. S. Coonar· 1 shared C. Martins· 1 shared D. M. Rassl· 1 shared D. Macias· 1 shared D. Munoz-Espin· 1 shared D. Rassl· 1 shared D. Veroutis· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Peryt

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma

J. Obacz, R. Nibhani, T. S. Adams, J. C. Schupp, J. A. Valer, N. Veale, G. Aresu, A. S. Coonar, A. Peryt, G. Biffi, N. Kaminski, H. E. Francies, D. Rassl, M. Garnett, R. C. Rintoul, S. J. Marciniak

This study presents a single-cell transcriptomic atlas of human pleura, identifying stromal heterogeneity and informing in vitro models of mesothelioma.

bioRxiv · Dec 3, 2022 · PreprintCancer Biology

A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer

E. Gonzalez-Gualda, D. Macias, S. Morsli, E. Martin, H.-L. Ou, M. Denholm, I. Olan, R. Hoffmann, M. Dane, D. Veroutis, G. Medrano, F. Mulero, C. Martins, M. Barbacid, V. Gorgoulis, , D. Munoz-Espin

This study shows platinum chemotherapy induces a senescent secretome in lung cancer that promotes tumor growth via the TGFβR1/Akt-mTOR axis, and targeting this pathway reduces tumor burden.

bioRxiv · Aug 1, 2022 · PreprintCancer Biology